JAZZ
Jazz Pharmaceuticals plc
$157.02
Earnings Summary
Revenue | $932.88Mn |
Net Profits | $34.67Mn |
Net Profit Margins | 3.72% |
Highlights
Jazz Pharmaceuticals plc’s revenue jumped 24.08% since last year same period to $932.88Mn in the Q2 2022. On a quarterly growth basis, Jazz Pharmaceuticals plc has generated 14.64% jump in its revenue since last 3-months.
Jazz Pharmaceuticals plc’s net profit jumped 109.54% since last year same period to $34.67Mn in the Q2 2022. On a quarterly growth basis, Jazz Pharmaceuticals plc has generated 2004.74% jump in its net profits since last 3-months.
Jazz Pharmaceuticals plc’s net profit margin jumped 107.69% since last year same period to 3.72% in the Q2 2022. On a quarterly growth basis, Jazz Pharmaceuticals plc has generated 1735.9% jump in its net profit margins since last 3-months.
Earnings per share (EPS) Estimates
Earnings per share (EPS) estimates of the Jazz Pharmaceuticals plc post its latest quarter earnings
EPS Estimate Current Quarter | 3.84 |
EPS Estimate Current Year | 3.84 |
Highlights
Jazz Pharmaceuticals plc’s earning per share (EPS) estimates for the current quarter stand at 3.84 - a 5.49% jump from last quarter’s estimates.
Jazz Pharmaceuticals plc’s earning per share (EPS) estimates for the current year stand at 3.84.
Key Ratios
Key ratios of the Jazz Pharmaceuticals plc post its Q2 2022 earnings
Return on Assets (ROA) | 0.04 |
Return on Equity (ROE) | -0.01 |
Dividend Per Share (DPS) | 0 |
Highlights
Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Jazz Pharmaceuticals plc’s return on assets (ROA) stands at 0.04.
The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Jazz Pharmaceuticals plc’s return on equity (ROE) stands at -0.01.
Jazz Pharmaceuticals plc declared 0 dividend per share during the earnings announcement for Q2 2022.
Earnings Calendar
| Earnings Date | Estimated EPS | Reported EPS | Surprise % |
|---|---|---|---|
2022-05-04 | 3.84 | 3.73 | -2.86% |
Company Information
Jazz Pharmaceuticals plc is a global biopharmaceutical company dedicated to developing and commercializing life-changing medicines that transform the lives of patients with serious diseases - often with limited or no options. Jazz Pharmaceuticals plc has a diverse portfolio of marketed medicines and novel product candidates, from early- to late-stage development, in key therapeutic areas. The company's focus is in neuroscience, including sleep and movement disorders, and in oncology, including hematologic and solid tumors. They actively explore new options for patients including novel compounds, small molecule advancements, biologics and innovative delivery technologies. Jazz is headquartered in Dublin, Ireland and has employees around the globe, serving patients in more than 90 countries.
Organisation | Jazz Pharmaceuticals plc |
Headquarters | Fifth Floor, Waterloo Exchange, Ireland |
Employees | 1.94K |
Industry | Health Technology |